Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, 27514, USA,
Curr Infect Dis Rep. 2010 May;12(3):165-73. doi: 10.1007/s11908-010-0099-y.
As drug-resistant falciparum malaria has continued to evolve and spread worldwide, artemisinin-based combination therapies (ACT) have become the centerpiece of global malaria control over the past decade. This review discusses how advances in antimalarial drug resistance monitoring and rational use of the array of ACTs now available can maximize the impact of this highly efficacious therapy, even as resistance to artemisinins is emerging in Southeast Asia.
随着耐药性恶性疟原虫在全球范围内不断演变和传播，以青蒿素为基础的联合疗法（ACT）在过去十年中已成为全球疟疾控制的核心。本文讨论了如何在青蒿素耐药性监测和合理使用现有各类 ACT 方面取得进展，即使在东南亚出现抗青蒿素耐药性的情况下，也能最大限度地发挥这种高效疗法的作用。
